ASLAN Pharmaceuticals announces $18m private placement

The financing closed on 25 February.

ASLAN Pharmaceuticals has entered into a securities purchase agreement to raise gross proceeds of $18m, resulting from the sale of its ordinary shares through a private placement to new institutional investors, Vivo Capital and Surveyor Capital.

The clinical-stage immunology focused biopharmaceutical company will issue an aggregate of 25,568,180 ordinary shares, equivalent to 5,113,636 American Depositary Shares (ADSs), at an equivalent price of $3.52 per ADS, equal to the last closing price of the company’s ADSs.

According to ASLAN Pharmaceuticals CEO Dr. Carl Firth, the additional resources from the private placement will fund their ongoing study of ASLAN004 in atopic dermatitis in early March and look towards initiating the company’s phase 2b program later in 2021.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia